​

Relmada Therapeutics (RLMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RLMD Stock Forecast

Relmada Therapeutics (RLMD) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $5.67, with a high of $8.00 and a low of $2.00. This represents a 698.59% increase from the last price of $0.71.

- $1 $2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $5.67 Low: $2 Last Closed Price: $0.71

RLMD Stock Rating

Relmada Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (42.86%), 3 Hold (42.86%), 1 Sell (14.29%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 3 3 Strong Sell Sell Hold Buy Strong Buy

RLMD Price Target Upside V Benchmarks

TypeNameUpside
StockRelmada Therapeutics698.59%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%
IdeaPsychedelic Stocks List199.06%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.71$0.71$0.71
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25--3--3
May, 25--3--3
Apr, 25--3--3
Mar, 25--3--3
Feb, 25--3--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 05, 2024Andrea TanGoldman Sachs$2.00$2.95-32.20%181.69%
Oct 13, 2022Andrew TsaiJefferies$8.00$6.4823.46%1026.76%
Oct 13, 2022Jay OlsonOppenheimer$7.00$6.753.70%885.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024JefferiesBuyupgrade
Jun 05, 2024Goldman SachsSelldowngrade
Oct 13, 2022OppenheimerPerformdowngrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.28-----
Avg Forecast$-3.28$-2.74$-1.15$-1.36$-0.49$-0.71
High Forecast$-3.25$-2.69$-0.27$-0.08$-0.09$-0.71
Low Forecast$-3.30$-2.79$-2.02$-2.64$-0.88$-0.71
Surprise %------

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$2.46M$10.00M$32.45M$202.15M
High Forecast--$2.46M$10.00M$32.45M$202.15M
Low Forecast--$2.46M$10.00M$32.45M$202.15M
Surprise %------

Net Income Forecast

$-100M $-80M $-60M $-40M $-20M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-98.79M-----
Avg Forecast$-98.79M$-82.47M$-47.17M$-40.90M$-14.60M$-21.37M
High Forecast$-97.72M$-80.96M$-8.22M$-2.33M$-2.58M$-21.37M
Low Forecast$-99.20M$-83.98M$-60.81M$-79.34M$-26.62M$-21.37M
Surprise %------

RLMD Forecast FAQ

Is Relmada Therapeutics stock a buy?

Relmada Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Relmada Therapeutics is a favorable investment for most analysts.

What is Relmada Therapeutics's price target?

Relmada Therapeutics's price target, set by 7 Wall Street analysts, averages $5.67 over the next 12 months. The price target range spans from $2 at the low end to $8 at the high end, suggesting a potential 698.59% change from the previous closing price of $0.71.

How does Relmada Therapeutics stock forecast compare to its benchmarks?

Relmada Therapeutics's stock forecast shows a 698.59% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%), leading the psychedelic stocks list (199.06%) investment idea.

What is the breakdown of analyst ratings for Relmada Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Relmada Therapeutics’s EPS forecast?

Relmada Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.15, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-1.36 in 2026, $-0.49 in 2027, and $-0.71 in 2028.

What is Relmada Therapeutics’s revenue forecast?

Relmada Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $2.46M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10M, followed by $32.45M for 2027, and $202.15M for 2028.

What is Relmada Therapeutics’s net income forecast?

Relmada Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-47.167M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-40.9M in 2026, $-14.598M in 2027, and $-21.37M in 2028.